MPPE1 and neoplasm: Mechanistically, the combination of capivasertib and adavosertib resulted in an inflamed tumor microenvironment characterized by increased expression of markers of immunogenic cell death, including calreticulin, and notable increases in cDC1 and NK cell infiltration.